Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
2.710
+0.170 (6.69%)
May 13, 2025, 4:00 PM - Market closed

Scinai Immunotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
4.8-6.5-5.8-8.21-1.39
Upgrade
Depreciation & Amortization
1.650.510.560.470.76
Upgrade
Loss (Gain) From Sale of Assets
-----0.05
Upgrade
Asset Writedown & Restructuring Costs
--0.21--
Upgrade
Stock-Based Compensation
0.681.141.62.762.95
Upgrade
Other Operating Activities
-13.57-3.74-4.11-3.15-20.3
Upgrade
Change in Accounts Receivable
0.14-0.290.140.06-0.17
Upgrade
Change in Accounts Payable
-0.16-0.15-0.180-4.73
Upgrade
Change in Other Net Operating Assets
0.13-0.360.310.640.37
Upgrade
Operating Cash Flow
-6.34-9.38-7.27-7.43-22.56
Upgrade
Capital Expenditures
-0.01-0.64-0.84-0.14-1.91
Upgrade
Sale of Property, Plant & Equipment
----0.05
Upgrade
Other Investing Activities
----0.01
Upgrade
Investing Cash Flow
-0.01-0.64-0.84-0.14-1.85
Upgrade
Long-Term Debt Repaid
-----0.39
Upgrade
Net Debt Issued (Repaid)
-----0.39
Upgrade
Issuance of Common Stock
3.440.140.9321.434.65
Upgrade
Other Financing Activities
-0.955.84--
Upgrade
Financing Cash Flow
3.441.096.7821.434.27
Upgrade
Foreign Exchange Rate Adjustments
-0.01-0.27-1.980.580.53
Upgrade
Net Cash Flow
-2.92-9.21-3.314.44-19.61
Upgrade
Free Cash Flow
-6.35-10.02-8.1-7.57-24.47
Upgrade
Free Cash Flow Margin
-964.59%----
Upgrade
Free Cash Flow Per Share
-7.87-25.65-42.97-53.60-220.83
Upgrade
Cash Interest Paid
-0.830.92-0.01
Upgrade
Levered Free Cash Flow
-3.61-5.9-5.52-2.71-1.88
Upgrade
Unlevered Free Cash Flow
-3.61-5.9-5.52-2.71-1.66
Upgrade
Change in Net Working Capital
-0.150.85-0.06-0.994.88
Upgrade
Updated Nov 22, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q